Application Research of Standardized Management Pathways for Cancer Pain Based on Hydromorphone Sustained-Release Tablets: A Multicenter Randomized Controlled Trial

Start Date01 Oct 2026

Sponsor / Collaborator

Shandong Provincial Hospital

ChiCTR2600132902

/ Not yet recruitingNot ApplicableIIT

Effects of different analgesics on postoperative nausea and vomiting during anesthesia for hysteroscopic surgery

Start Date01 Oct 2026

Sponsor / Collaborator-

ChiCTR2600128746

/ SuspendedPhase 4IIT

Effects of Intrathecal Hydromorphone on Acute Postoperative Pain Following Abdominal Surgery

Start Date01 Sep 2026

Sponsor / Collaborator-

100 Clinical Results associated with Hydromorphone Hydrochloride

100 Translational Medicine associated with Hydromorphone Hydrochloride

100 Patents (Medical) associated with Hydromorphone Hydrochloride

2,948

Literatures (Medical) associated with Hydromorphone Hydrochloride

01 Nov 2026·BURNS

Analgesic use and pain burden in adults with major burns: A retrospective analysis

Article

Author: Sousse, Linda E ; Nelson, Alexandra D ; Williams, Felicia N ; Agala, Chris B ; King, Booker T ; McKinzie, Brian P ; Deliwala, Ishani H

BACKGROUND:

Pain control in severe burns remains challenging due to physiological factors affecting drug metabolism and efficacy. This study characterizes the most frequent combinations of pain medication, dosages of opioids and non-opioids over time, and their correlation with pain management in adults.

METHODS:

A single-center retrospective analysis of patients ≥ 18 years of age admitted to University of North Carolina Jaycee Burn Center with ≥ 20% total body surface area (TBSA) burn injury between 2020 and 2024 was performed. Records were abstracted for demographics, prescription pain medication management, and numerical rating scale (NRS) pain scores. Generalized linear and mixed models assessed average daily pain scores and morphine milligram equivalents (MME), adjusted for age, TBSA burn, and inhalation injury.

RESULTS:

140 patients were included (age: 32 ± 7 years; 72% male; TBSA burn 37 ± 19% [range: 20-98%]; length of stay: 42 ± 54 days; 19% inhalation injury). 88% survived and most injuries were flame-related (76%). Opioid-only regimens accounted for 7% of prescribing medications, non-opioid-only 15%, and multimodal regimens 78%. Acetaminophen and hydromorphone were most frequently administered (17%), followed by acetaminophen, hydromorphone, and oxycodone (14%) and acetaminophen, fentanyl, and oxycodone (13%). Patients receiving multimodal or opioid-only regimens demonstrated lower and more stable pain trajectories than those receiving non-opioids alone. Hydromorphone use increased with burn severity and was highest in patients with > 80% TBSA. Although opioid requirements declined over time, patients with burns > 40% TBSA had significantly higher MME at day 25 compared with moderate burns (451 ± 980 vs 237 ± 388; p = 0.023).

CONCLUSIONS:

Multimodal analgesia predominated and was associated with improved pain stability. Persistent opioid requirements in larger burns highlight the impact of burn-related metabolic alterations and support development of individualized analgesic strategies to optimize dosing and reduce prolonged opioid exposure.

01 Sep 2026·JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Rapid Relief of Breathlessness With Fast-Acting Opioids and Benzodiazepines: A Systematic Review

Review

Author: Haubner, André ; Oluyase, Adejoke O ; Higginson, Irene J

CONTEXT:

Breathlessness can peak within minutes. Centrally acting drugs are used for rapid relief, but evidence is unclear.

OBJECTIVE:

To assess the effectiveness and safety of fast-acting drugs affecting the central nervous system for spontaneous breathlessness with outcomes measured ≤20 minutes post-treatment.

METHODS:

A systematic review with narrative synthesis. Searches included CENTRAL, MEDLINE (Ovid), and Embase (Ovid) up to September 2025, reference screening and trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform). We included randomized controlled trials (RCTs) in adults with advanced or severe acute disease testing opioids, benzodiazepines, antipsychotics, or cannabinoids.

RESULTS:

Eleven trials (n = 334) contributed 15 comparisons; 13 compared an opioid with placebo or another opioid; mostly small crossover trials, varying in route, dose, and setting. No trial investigated antipsychotics or cannabinoids. Two small trials showed a relevant benefit over placebo: intravenous morphine (mean difference -1.8 cm; 95% CI -3.0 to -0.6) and subcutaneous morphine (-1.1 cm; -1.9 to -0.3; high risk of bias). Trials of inhaled opioids, intranasal fentanyl, and oral hydromorphone showed no benefit compared to placebo. Midazolam was evaluated in two trials; neither showed a benefit compared to placebo or morphine; both had important methodological limitations. Adverse-event monitoring was limited. In two acute-care morphine trials, serious adverse events were more frequent in the morphine arms.

CONCLUSION:

Instead of use as routine care, fast-acting opioids (morphine subcutaneous or intravenous) should be considered as a second step if non pharmacological measures have failed. Further research is needed, especially for other centrally acting drugs and adverse effects.

08 Jul 2026·Oxford Medical Case Reports

Hydromorphone-induced choreiform dyskinesia in a patient with homozygous sickle cell disease: a reversible adverse effect

Article

Author: El Masry, Michael ; Ghobrial, Nader ; Rajab, Islam ; Saife, Sakeena ; Rahman, Rayan A

Abstract:

Background:

Sickle Cell Disease (SCD) is a type of chronic hemoglobinopathy with vaso-occlusive pain crises that requires aggressive pain management with opioids.Hydromorphone is commonly used in the management of pain in patients with SCD, particularly when vaso-occlusive crises require prolonged opioid therapy. While opioid-induced neurotoxicity is a well-recognized complication, usually presenting as delirium, agitation, or myoclonus, choreiform dyskinesias are rare and only infrequently reported. New-onset involuntary movements in patients with SCD may be concerning for cerebrovascular or metabolic complications, prompting extensive diagnostic evaluations. Recognition of opioid-induced choreiform dyskinesia is important, since symptoms are usually reversible with opioid dose reduction or discontinuation, thus offering early management and the avoidance of unnecessary investigations.

Case Report:

A 33-year-old African American woman with homozygous sickle cell disease (HbSS) was admitted for pleuritic chest pain, fever, abdominal pain, and sweating, suspected to be acute chest syndrome or a vaso-occlusive pain crisis. She had a history of recurrent vaso-occlusive crises requiring hospitalizations and opioid therapy. She had no history of cerebrovascular events, movement disorders, psychiatric illness, or exposure to dopamine-modulating medications. She had no significant family history.On day 25 of hospitalization, she developed new, involuntary, non-rhythmic choreiform movements affecting the upper limbs and face while on high-dose IV hydromorphone. She remained alert and oriented without any focal neurologic signs or metabolic issues. The hydromorphone was stopped, and the movements completely resolved within 24 hours. When trying a lower dose, the movements did not recur. Neurology advised that no further imaging or testing was needed given the rapid, full improvement.

Conclusions:

Dyskinesia is a rare but reversible complication of opioid therapy and may be caused by hydromorphone. It is important to recognize this side effect to prevent unnecessary testing, particularly in patients with sickle cell disease, who may otherwise undergo an extensive neurologic workup.

News (Medical) associated with Hydromorphone Hydrochloride

10 Sep 2026

·www.biospace.com

Adneuris Therapeutics Presents Novel Data on Lead Candidate, Cebranopadol for the Treatment of Moderate-to-Severe Acute Pain at PAINWeek 2026

Adneuris unveiled new abuse potential data demonstrating that cebranopadol's abuse potential may be lower than that of Schedule II and Schedule IV pain drugs, further differentiating its dual NOP/MOP mechanism from drugs like oxycodone. The Phase 3 ALLEVIATE studies met their primary efficacy endpoints for cebranopadol for the treatment of moderate-to-severe acute pain, with significant reductions in pain intensity observed across both soft- and hard-tissue surgical pain models. These data reinforce Adneuris' continued progress toward a planned New Drug Application (NDA) submission later this year. MONMOUTH JUNCTION, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma advancing a new kind of pain medicine, today announced novel data presented for its lead investigational therapy, cebranopadol, at PAINWeek 2026, taking place September 8-11 in Las Vegas, NV. The data demonstrating cebranopadol’s potential efficacy in moderate-to-severe acute pain and reduced abuse potential, add to the growing body of evidence supporting its differentiated pro an investigational, first-in-class, dual nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptor (dual-NMR) agonist. Among the new data presented at PAINWeek are results from a comprehensive abuse potential assessment of cebranopadol. The assessment drew on behavioral pharmacology and human abuse potential studies, along with an analysis of abuse- and withdrawal-related adverse events across a large-scale clinical program. Key findings from the abuse potential include data demonstrating: Lower abuse potential: In recreational opioid users, cebranopadol at doses up to 2.5 times the anticipated maximum therapeutic dose showed lower abuse potential compared with Schedule II opioids hydromorphone and oxycodone and Schedule IV opioid tramadol. Low incidence of euphoria and withdrawal-related events: Cebranopadol was associated with a low incidence of euphoria-like events, while withdrawal-related adverse events following abrupt discontinuation were rarely reported and were not more common than placebo in studies of up to 14 weeks. Reduced abuse-related signals in preclinical models: Preclinical studies showed cebranopadol had a lower tendency to reinforce drug-seeking behavior than selective MOP agonists, along with weak physical dependence potential. Drug discrimination studies further indicated that cebranopadol’s NOP receptor activity tempers MOP agonist effects, a mechanism believed to underlie its reduced abuse potential. Taken together, the data suggest cebranopadol may have a meaningfully lower abuse potential than selective full and partial MOP agonists, a critical body of evidence for the Company as it moves toward NDA submission. “Each year, roughly 80 million Americans experience acute pain 1 , and for too many, effective pain relief can come with concerns about the dependence, addiction and misuse associated with drugs like oxycodone. That is the challenge we built Adneuris to address,” said James Hackworth, Ph.D., Cebranopadol Development Lead at Adneuris Therapeutics. “Cebranopadol was developed with a fundamentally different approach. Through its dual NOP/MOP receptor mechanism, it is designed to provide meaningful pain relief while potentially mitigating many of the risks associated with existing treatments. These data further reinforce that differentiated pro add to the growing body of evidence supporting cebranopadol’s potential to fill in a critical treatment gap for patients and physicians managing moderate-to-severe acute pain with the promise of a better benefit-risk profile. As we advance toward our planned NDA submission later this year, we remain focused on building the evidence needed to potentially change how moderate-to-severe acute pain is treated.” Adneuris also presented results from its two pivotal Phase 3 studies, ALLEVIATE-1 and ALLEVIATE-2, evaluating cebranopadol for moderate-to-severe acute pain following abdominoplasty and bunionectomy, respectively. Key findings from the Phase 3 studies include: ALLEVIATE-1: In a study evaluating participants undergoing abdominoplasty, cebranopadol 400µg demonstrated a significant reduction in pain intensity from 4-48 hours compared with placebo (LS mean difference -59.2; p<0.001). ALLEVIATE-2: In a study evaluating participants undergoing bunionectomy, cebranopadol 400µg demonstrated a significant reduction in pain intensity from 2-48 hours compared with placebo (LS mean difference -56.1; p<0.001). Oxycodone also demonstrated a significant reduction versus placebo (LS mean difference -29.1; p=0.031). Rescue medication use and tolerability: Across both studies, rescue medication use was significantly lower with cebranopadol compared with placebo (p<0.001). Cebranopadol was well tolerated, with no drug-related serious adverse events reported. Together, the ALLEVIATE studies demonstrate cebranopadol's potential to provide effective analgesia across both soft- and hard-tissue surgical pain models, supporting its development as a treatment option for moderate-to-severe acute pain. The data presented at PAINWeek further support cebranopadol’s potential as a differentiated treatment for moderate-to-severe acute pain and mark another important step forward for Adneuris since its launch in July 2026. Together with the Company’s recent strategic partnerships and progress toward a planned NDA submission later this year, the presentations reflect Adneuris’ continued momentum in advancing cebranopadol. About Adneuris Therapeutics Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma, is dedicated to developing new therapies for people living with pain. Guided by a patient-first approach, the company is focused on advancing innovative science with the goal of improving pain management and addressing unmet patient needs. Adneuris is committed to helping shape the future of pain care through research, collaboration, and a focus on delivering meaningful treatment options. For more information, visit . About Tris Pharma, Inc. Tris Pharma, Inc. is a privately held, innovation-driven biopharmaceutical commercial-stage company that is applying drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, and disorders of the central nervous system into advanced, targeted drug delivery. Tris markets a portfolio of best-in-class ADHD products and is developing a robust pipeline of differentiated near-term drug candidates. For more information, visit . About Cebranopadol Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors (a dual-NMR agonist), for the treatment of moderate-to-severe pain, as well as opioid use disorder (OUD). Studied in over 34 clinical trials in more than 2,400 subjects, cebranopadol's pro been well characterized in pain management studies, demonstrating positive clinical results in acute pain, chronic pain and diabetic neuropathic pain with a favorable safety profile. The FDA granted Fast Track Designation to cebranopadol for chronic low back pain, and if approved, it has the potential to become the first dual-NMR agonist to provide robust pain relief with a reduced risk of dependence, respiratory depression, or abuse potential than selective MOP agonists such as oxycodone. Cebranopadol's novel mechanism of action also has potential in treating patients with substance use disorders (SUDs). The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Tris a five-year grant of up to $16.6 million to study cebranopadol's potential to treat OUDs and SUDs. Contact: Cheryl Patnick Tris Pharma 732-823-4940 Media Contact: Madelin Hawtin LifeSci Communications MHawtin@lifescicomms.com Lopez, Andreaa,*; Menzie, Ann M.a; Kenderes, Michaelb; Rubin, Jaime L.a. A real-world databaseanalysis of the prevalence of pain medication use in the United States. PAIN Reports 11(1):e1396,February 2026. | DOI: 10.1097/PR9.0000000000001396

03 Sep 2026

·www.fiercepharma.com

Fresenius unit dinged in FDA warning letter flagging 'complaint trend' from customers

Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah is contending with a warning letter from the FDA. The FDA reprimand, dated Aug. 25 and posted to the agency’s website this week, follows an inspection of Fresenius Medical Care’s plant in Ogden, Utah, in early March of this year. In two observations, the FDA’s concerns focused on the company’s failure to thoroughly investigate customer complaints about its products, plus lackluster inspection protocols at the plant to suss out potential particulate contamination. Last August, the Fresenius unit kicked off its own investigation due to a “complaint trend” around “leaking bags” of a certain dialysis solution product it sells, per the FDA write-up, which noted that Fresenius Medical Care eventually received 35 complaints related to some 156 bags from multiple batches. At the time, the company attributed the issue to holes caused during the bag printing process, per the FDA. The manufacturing defect posed the risk of peritonitis, or infection causing the tissue inside the abdomen to become inflamed. But the company “instead assigned the lowest severity level” to the issue, the regulator wrote. The company did launch a related recall this past April, but the FDA seemed to chide Fresenius Medical Care because it “chose not to conduct a recall following the results of your August 2025 investigation.” “Your decision not to recall these batches at that time exposed peritoneal dialysis (PD) patients to potentially non-sterile drug products,” the regulator continued. The FDA believes the Fresenius unit has more work to do yet in assuring it detects leaking units during manufacturing and is able to stop their release and distribution, which the FDA called “especially concerning considering the numerous complaints, Field Alert Reports, and recalled batches in the last three years” at the facility. In a second observation, the FDA also reprimanded Fresenius Medical Care over the Ogden facility’s visual inspection program, which the agency deemed inadequate to ensure sterile drugs were “essentially free” of visible particulates. The issue came down to the company’s failure to “appropriately qualify personnel who performed visual inspections of injectable products,” the FDA explained. In particular, the qualification kits used by the company “did not include adequately representative visible particles” across characteristics like size, and the company’s qualification records weren’t detailed enough for investigators to determine the qualifications of staff who performed visual inspections, the regulator added. Given the nature of the observations, the FDA is recommending that Fresenius Medical Care enlist a current good manufacturing practices (cGMP) consultant to help right the ship at the Ogden plant. Sister company Fresenius Kabi has also grappled with its share of manufacturing pitfalls this summer, recently launching separate recalls of an Actemra biosimilar over the potential presence of glass particles and a batch of morphine sulfate, which had been mislabeled and could instead contain the separate opioid Dilaudid.

12 Aug 2026

·www.fiercepharma.com

Fresenius pulls one batch of Actemra biosim over glass particle concerns

Fresenius Kabi is yanking a batch of another product in the U.S., shortly after initiating a separate recall tied to mislabeled pain medicine. Fresenius has issued a recall of its biosimilar Tyenne (tocilizumab-aazg) injection in 20 ml vials, after a company investigation found the product contained glass particles. It likely goes without saying that injecting medication contaminated with glass particulates can have unintended consequences. Doing so could cause irritation, pain or swelling at the infusion site, as well as potential inflammation of the veins, Fresenius said in a recall notice posted on the FDA’s website. In more serious cases, injected glass particles can cause blockage and clotting of blood vessels, stopping blood flow to organs and potentially leading to life-threatening clots in the lungs. At its worst, an adverse event from such a product could lead to permanent organ damage or death, the company warned. As of Aug. 12, Fresenius Kabi had not received any adverse event reports tied to the recall, a company spokesperson confirmed to Fierce. Tyenne is a biosimilar referencing Roche’s IL-6 receptor antagonist Actemra. It is used to treat certain adults with severely active rheumatoid arthritis, and those with giant cell arteritis. Fresenius’ drug is also cleared in pediatric populations for active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis, and in adults and kids with CAR T cell-induced severe or life-threatening cytokine release syndrome. Fresenius’ recall covers a single lot of Tyenne, which was distributed across the U.S. and carried an expiration date of August 2028. Glass particles shedding or otherwise turning up in vials of the drug have prompted multiple other product pulls in recent years. As recently as May, generics powerhouse Sun Pharma yanked one lot of a chemotherapy in the U.S. after the discovery of glass particles in some vials of the product—used to treat ovarian cancer, Kaposi sarcoma and multiple myeloma—during production. In 2024, Gilead Sciences recalled one batch of its COVID-19 med, Veklury, after detecting a glass particle in a vial, which was flagged by a customer complaint. And the issue also led to similar product pulls for GSK and Pfizer the year before that, to name just a few examples. As for Fresenius, the German-headquartered drugmaker publicized a separate U.S. recall last week focused not on particulate contamination, but labeling gone wrong. In that notice, Fresenius Kabi said it was pulling one lot of morphine sulfate injection that was mislabeled and could contain a prefilled syringe of the more potent opioid dilaudid. Editor's note: This story has been updated with a comment from a Fresenius Kabi spokesperson.

Drug Approval

100 Deals associated with Hydromorphone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00839	Hydromorphone Hydrochloride	N02AA03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Severe pain	United States	Hikma Pharmaceuticals USA, Inc.	14 Dec 2023
Cancer Pain	Japan	Daiichi Sankyo Co., Ltd.	01 Jun 2017
Pain, Postoperative	United States	SpecGx LLC	01 Mar 2010
Pain	United States	Fresenius Kabi USA LLC	11 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	-	ALZA Corp.	13 Dec 2006
Chronic osteoarthritis	Phase 3	-	ALZA Corp.	14 Nov 2006
Chronic Pain	Phase 3	United States	Purdue Pharma LP	01 Jul 2005
Osteoarthritis, Hip	Phase 3	-	ALZA Corp.	01 Nov 2003
Osteoarthritis, Knee	Phase 3	-	ALZA Corp.	01 Nov 2003
Anesthesia	Phase 3	-	Johnson & Johnson	-
Acute Pain	Phase 2	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 2025
Chest Pain	Phase 2	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 2025
Analgesia	Phase 2	-	ALZA Corp.	14 Dec 2006
Early Stage Breast Carcinoma	Phase 1	China	Xian-Janssen Pharmaceutical Ltd.	01 Dec 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04230681 (Pubmed \| Paediatr Anaesth)	Early Phase 1	-	180	Hydromorphone	qxvdzxejrd(smgllbofry) = kyupdemfmn wivydzquvm (hkkcckalnu ) View more	Positive	18 Jun 2026
				Fentanyl	qxvdzxejrd(smgllbofry) = cngwjvcwfv wivydzquvm (hkkcckalnu ) View more
NCT03726268 (OSPREy, CTgov)	Phase 4	Pain, Postoperative	907	Methadone (Short-stay, IV Methadone)	mydtcjeqrw(kksodnfhkj) = vlvqwlxvah njurvnkndj (majpmgnivm, 15.50) View more	-	19 Nov 2025
				Fentanyl+Hydromorphone+Sufentanil+Morphine (Short-stay, IV Short-acting Opioids)	mydtcjeqrw(kksodnfhkj) = jlqsdhfhbc njurvnkndj (majpmgnivm, 11.60) View more
ESMO2025	Not Applicable	Neoplasms	371	Subcutaneous hydromorphone PCA	kilztfogbx(qsoqjgpkni) = No case of interruption occurred, and all the patients were satisfied with pain control. eekfnelgkx (izupellbkm ) View more	Positive	17 Oct 2025
NCT03592992 (Pubmed \| Anesth Analg)	Phase 4	Analgesia	126	Hydromorphone 75 μg	aaztrjmubq(apdikvrito) = fqdjtlqezn krwjvjpzgp (swtelkjwsj, 1.5) View more	Non-inferior	10 Jun 2025
				Morphine 150 μg	aaztrjmubq(apdikvrito) = xqisxzvsns krwjvjpzgp (swtelkjwsj, 1.7) View more
NCT04752033 (Pubmed \| Mayo Clin Proc Innov Qual Outcomes)	Phase 4	Pain, Postoperative	-	Intrathecal Morphine	nmsrbdswwv(glhwgcjihu) = No serious adverse events were observed throughout the study duration dskgphillg (xmhnfjsgtn ) View more	Negative	01 Apr 2025
				Intrathecal Hydromorphone
NCT04300231 (CTgov)	Phase 3	Pain, Postoperative	160	/hydromorphone 0.05mg/ml+bupivacaine (Thoracic Epidural)	evhxdwdsxg(ryxrxhfkjf) = auktklzqel ukeanxqlsy (inhwabtmba, pdygzambis - bimcngabyr) View more	-	10 Feb 2025
				injectable saline+Liposomal bupivacaine+bupivacaine (Rectus Sheath Block)	evhxdwdsxg(ryxrxhfkjf) = tblfpxzyjb ukeanxqlsy (inhwabtmba, dsanpqegxa - sqwudsdvsd) View more
NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	pmmbkhqpov = ktmhmvxjwo ebwpevzeue (ymcjiyeaga, nshwqliknn - rzwpybrcoc) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	pmmbkhqpov = pdfjccdzvy ebwpevzeue (ymcjiyeaga, mlkngxyfpd - ggygfjhlkr) View more
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	anwhsbuiir(idqqqwfccl) = fzqezvxpzl jobuzjhdwz (lxnnoqyxsf, bflzruraco - cduxfuqagu) View more	-	17 Oct 2024
NCT04258631 (CTgov)	Phase 4	Female Genital Neoplasms \| Pain	105	Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine))	bcqkmkniai(wopiacahxe) = bgzsujpcdh nqjnfwnlag (xhqsxmnbxs, xnbkqidagm - owtlsxfkwp) View more	-	16 Oct 2024
				Laparotomy+Hydromorphone+Liposomal Bupivacaine (Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone))	bcqkmkniai(wopiacahxe) = kaudnkjneo nqjnfwnlag (xhqsxmnbxs, axintzxgmk - acgizupwtq) View more
NCT02939209 (Pubmed \| Can Anaesth Soc J)	Phase 4	-	73	Hydromorphone 2 mg	pofigdasze(hotpplkjtq) = qxpzhgenrw zcvlqhpntq (cakrbutene, 2.4)	Negative	01 Jun 2024
				Placebo	pofigdasze(hotpplkjtq) = tlnjfynnnf zcvlqhpntq (cakrbutene, 2.3)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis